REGULATION OF FOCAL ADHESION TURNOVER BY ERBB RECEPTOR SIGNALING AND PRECLINICAL IMPLICATIONS FOR ERBB-2+INVASIVE BREAST CANCER MODELS

被引：0
|
作者：
Alaoui-Jamali, Moulay [1 ]
机构：
[1] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst, Segall Comprehens Canc Ctr,Dept Med & Oncol, Montreal, PQ H3T 1E2, Canada
来源：
ANTICANCER RESEARCH | 2008年 / 28卷 / 5C期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页码：3187 / 3188
页数：2
相关论文
共 50 条
  • [21] Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth
    L Yang
    Y Li
    Y Zhang
    Cell Death & Disease, 2014, 5 : e1211 - e1211
  • [22] Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer
    Naderi, Ali
    Meyer, Michelle
    Dowhan, Dennis H.
    NEOPLASIA, 2012, 14 (04): : 283 - +
  • [23] Immunohistochemical expression of internal and external ErbB‐2 domains in invasive breast cancer
    Claudio Ceccarelli
    Donatella Santini
    Michela Gamberini
    Mario Taffurelli
    Pasquale Chieco
    Simonetta Piana
    Stefano Pileri
    Domenico Marrano
    Breast Cancer Research and Treatment, 1999, 58 : 107 - 114
  • [24] Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine
    Bijian, K.
    Lougheed, C.
    Su, J.
    Xu, B.
    Yu, H.
    Wu, J. H.
    Riccio, K.
    Alaoui-Jamali, M. A.
    BRITISH JOURNAL OF CANCER, 2013, 109 (11) : 2810 - 2818
  • [25] Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine
    K Bijian
    C Lougheed
    J Su
    B Xu
    H Yu
    J H Wu
    K Riccio
    M A Alaoui-Jamali
    British Journal of Cancer, 2013, 109 : 2810 - 2818
  • [26] Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
    Shah, Chirayu
    Miller, Todd W.
    Wyatt, Shelby K.
    McKinley, Eliot T.
    Olivares, Maria Graciela
    Sanchez, Violeta
    Nolting, Donald D.
    Buck, Jason R.
    Zhao, Ping
    Ansari, M. Sib
    Baldwin, Ronald M.
    Gore, John C.
    Schiff, Rachel
    Arteaga, Carlos L.
    Manning, H. Charles
    CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4712 - 4721
  • [27] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [28] Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness
    Behmoaram, Emy
    Bijian, Krikor
    Jie, Su
    Xu, Yingjie
    Darnel, Andrew
    Bismar, Tarek A.
    Alaoui-Jamali, Moulay A.
    AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (05): : 1540 - 1550
  • [29] Beyond HER2: Targeting the ErbB receptor family in breast cancer
    Drago, Joshua Z.
    Ferraro, Emanuela
    Abuhadra, Nour
    Modi, Shanu
    CANCER TREATMENT REVIEWS, 2022, 109
  • [30] Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer
    Ceccarelli, C
    Santini, D
    Gamberini, M
    Taffurelli, M
    Chieco, P
    Piana, S
    Pileri, S
    Marrano, D
    BREAST CANCER RESEARCH AND TREATMENT, 1999, 58 (02) : 107 - 114
12345